CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX)

Q: What does CUSIP 23284F105 represent in this 13F holders report?

CUSIP 23284F105 is the security identifier for CTMX - CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share used to aggregate holder disclosures.

Q: How many institutions held CTMX - CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share in Q2 2025?

82 institutional investors reported CTMX - CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 23284F105

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, par value $0.00001 per share
Shares outstanding: 217,291,620
Total 13F shares: 133,305,109
Share change: +88,021,897
Total reported value: $302,602,132
Put/Call ratio: 40%
Price per share: $2.27
Number of holders: 82
Value change: +$213,797,054
Number of buys: 55
Number of sells: 29

Quarterly Holders Quick Answers

What is CUSIP 23284F105?
CUSIP 23284F105 identifies CTMX - CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 23284F105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CTMX - CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Longitude Capital Partners V, LLC	13D/G	—	7.3%	11,538,461	$8,192,307	$0	13 May 2025	13D/G
TANG CAPITAL MANAGEMENT LLC	13F	Company	3.1%	6,717,825	$4,271,193	—	31 Mar 2025	13F
BVF INC/IL	13F	Company	2.4%	5,228,461	$3,324,256	—	31 Mar 2025	13F
VANGUARD GROUP INC	13F	Company	2.4%	5,117,376	$3,254,651	—	31 Mar 2025	13F
Prosight Management, LP	13F	Company	1.8%	3,930,008	$2,498,699	—	31 Mar 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	1.5%	3,234,035	$2,053,000	—	31 Mar 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	1.3%	2,826,276	$1,796,946	—	31 Mar 2025	13F
Point72 Asset Management, L.P.	13F	Company	1.2%	2,650,000	$1,684,870	—	31 Mar 2025	13F
Woodline Partners LP	13F	Company	0.76%	1,657,306	$1,053,715	—	31 Mar 2025	13F
Laurion Capital Management LP	13F	Company	0.6%	1,293,686	$822,526	—	31 Mar 2025	13F
BlackRock, Inc.	13F	Company	0.54%	1,166,384	$741,588	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.53%	1,156,000	$734,985	—	31 Mar 2025	13F
RA CAPITAL MANAGEMENT, L.P.	13F	Company	0.46%	1,000,000	$635,800	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.39%	857,958	$545,625	—	31 Mar 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.35%	762,930	$485,000	—	31 Mar 2025	13F
UBS Group AG	13F	Company	0.34%	746,788	$474,957	—	31 Mar 2025	13F
Assenagon Asset Management S.A.	13F	Company	0.33%	711,454	$452,342	—	31 Mar 2025	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.32%	686,208	$436,291	—	31 Mar 2025	13F
Congress Park Capital LLC	13F	Company	0.31%	673,686	$428,330	—	31 Mar 2025	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.27%	589,332	$374,696	—	31 Mar 2025	13F
SEI INVESTMENTS CO	13F	Company	0.22%	487,902	$310,208	—	31 Mar 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.21%	463,854	$294,547	—	31 Mar 2025	13F
Seven Fleet Partners LP	13D/G	—	0.2%	377,161	$267,784	$0	13 May 2025	13D/G
Formidable Asset Management, LLC	13F	Company	0.16%	353,840	$224,971	—	31 Mar 2025	13F
Tidal Investments LLC	13F	Company	0.16%	353,840	$224,971	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	0.15%	320,043	$203,483	—	31 Mar 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.14%	306,624	$194,952	—	31 Mar 2025	13F
Jeffrey B. Landau	3/4/5	Chief Business Officer	— mixed-class rows	266,736 mixed-class rows	$155,772	—	20 Aug 2024	3/4/5
Bank of New York Mellon Corp	13F	Company	0.11%	241,980	$153,851	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.07%	150,632	$95,772	—	31 Mar 2025	13F
Aspire Growth Partners LLC	13F	Company	0.04%	92,254	$88,610	—	31 Mar 2025	13F
Amy C. Peterson	3/4/5	EVP, Chief Development Officer	— class O/S missing	58,433	$80,678	—	16 Mar 2023	3/4/5
TWO SIGMA INVESTMENTS, LP	13F	Company	0.05%	116,475	$74,055	—	31 Mar 2025	13F
Lloyd A. Rowland	3/4/5	General Counsel	— class O/S missing	120,594	$72,236	—	18 Mar 2025	3/4/5
FMR LLC	13F	Company	0.05%	108,311	$68,864	—	31 Mar 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.05%	105,294	$66,946	—	31 Mar 2025	13F
Forefront Analytics, LLC	13F	Company	0.05%	100,070	$63,141	—	31 Mar 2025	13F
Universal- Beteiligungs- und Servicegesellschaft mbH	13F	Individual	0.04%	97,123	$61,751	—	31 Mar 2025	13F
MARSHALL WACE, LLP	13F	Company	0.04%	85,539	$54,746	—	31 Mar 2025	13F
Carlos Campoy	3/4/5	Chief Financial Officer	— class O/S missing	38,224	$52,776	—	16 Mar 2023	3/4/5
PRUDENTIAL FINANCIAL INC	13F	Company	0.04%	81,500	$51,818	—	31 Mar 2025	13F
Velan Capital Investment Management LP	13F	Company	0.03%	75,000	$47,685	—	31 Mar 2025	13F
Alison L. Hannah	3/4/5	Chief Medical Officer	— class O/S missing	31,898	$44,042	—	19 Jul 2022	3/4/5
GOLDMAN SACHS GROUP INC	13F	Company	0.03%	61,719	$39,241	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.03%	60,584	$38,519	—	31 Mar 2025	13F
Qube Research & Technologies Ltd	13F	Company	0.03%	54,808	$34,847	—	31 Mar 2025	13F
COMMONWEALTH EQUITY SERVICES, LLC	13F	Company	0.02%	54,243	$34,000	—	31 Mar 2025	13F
Miller Financial Services LLC	13F	Company	0.02%	51,000	$32,426	—	31 Mar 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.02%	47,036	$29,905	—	31 Mar 2025	13F
Russell Investments Group, Ltd.	13F	Company	0.02%	44,576	$28,340	—	31 Mar 2025	13F

Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) as of Q2 2025

As of 30 Jun 2025, CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) was held by 82 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 133,305,109 shares. The largest 10 holders included VR ADVISER, LLC, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, FMR LLC, ORBIMED ADVISORS LLC, Point72 Asset Management, L.P., Commodore Capital LP, PERCEPTIVE ADVISORS LLC, Vivo Capital, LLC, and FRANKLIN RESOURCES INC. This page lists 83 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.